Diagnostics startup Droplet Biosciences partners with Nvidia to speed cancer testing
Tweet
Share
E-mail
A smartphone with a displayed NVIDIA logo is placed on a computer motherboard in this illustration taken March 6, 2023. REUTERS/Dado Ruvic/Illustration
By Sneha S K
March 3 (Reuters) - Diagnostics firm Droplet Biosciences said on Tuesday it is collaborating with Nvidia to use the chipmaker's AI infrastructure to speed up post-surgery cancer test results.
The company has been using Nvidia Parabricks, a GPU-accelerated software suite, to speed up genomic data analysis for DNA sequencing.
Droplet said its method can detect residual disease in 24 hours by analyzing lymphatic fluid collected post surgery, compared to the four to six weeks it typically takes for tumor remnants to appear in blood-based tests.
"By leveraging NVIDIA Parabricks' acceleration, we've been able to compress some of our most computationally intensive steps from more than a day down to just a few hours," said Droplet's chief scientific officer, Wendy Winckler in a statement.
Droplet said it also realized operational benefits despite higher hourly costs for GPU compute, adding, "The dramatically reduced runtime results in a lower overall cost per sample."
"It's primarily allowing us to parallelize and run more of these (tests) at the same time and then, importantly, much faster," Wendy Winckler told Reuters.
Faster turnaround allows patients to get the results while still in the hospital, while avoiding extra visits or long waits for traditional blood tests.
The diagnostic startup's first clinical test is for HPV-negative head and neck cancer, validated under the Clinical Laboratory Improvement Amendments.
The test is available as part of an early access program with select partners, Winckler said. Its customers include the University of Pittsburgh Medical Center, Cleveland Clinic and Mayo Clinic.
Droplet is a member of NVIDIA Inception, an AI startup accelerator program, and an NVIDIA AI Enterprise customer.
By combining Nvidia's technology, Droplet Biosciences is transforming cancer detection, said Rory Kelleher, global head of business development for life sciences at NVIDIA, adding "the computational burden of deep-sequencing analysis has long been a bottleneck in cancer diagnostics".
(Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Romania adopts new measures to boost Danube waters to cool Cernavoda nuclear plant
- Texas seeks federal probe of airport washing facilities, Muslim group denounces move
- US Postal Service issues rules to tighten mail-in voting if court gives OK
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
